Competitive Advantages

CAR-T Cell Therapy Platform

Our CAR-T cell therapy portfolio consists of multiple autologous and allogeneic ("off-the-shelf") candidates with singletarget as well as "cocktail" combination. We are advancing a broad pipeline with selective targets in both laboratory and clinical trial settings. Currently, our autologous CAR-T candidates have demonstrated in early clinical studies against relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), T-cell ALL (T-ALL), non-Hodgkin's lymphoma(NHL), and T-cell lymphoblastic lymphoma with promising remission rates and well-tolerated adverse effect profile.

CAR-GDT (CAR-γδT) Cell Therapy Platform

Tumor Infiltrating Lymphocytes (TILs) Cell Therapy Platform


Clinical Development Stage:

Senl_1904B: Anti-CD19 CAR-T for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL)

Senl_B19: Anti-CD19 CAR-T for R/R NHL

Senl_H19: Anti-CD19 CAR-T for B-ALL and NHL post CAR-T relapse

Senl_NS7CAR: Anti-CD7 CAR-T for T-Cell (T-ALL) and NHL

Senl_H19x22P: Dual Anti-CD19 and Anti-CD22 CAR-T for R/R B-ALL and NHL

Preclinical/IND Enabling Stage:

Senl_ABUCAR7: Universal anti-CD7 CAR-T for R/R T-ALL and NHL

Senl_GDUCARxxx(undisclosed): Universal CAR-GDT for R/R acute myeloid leukemia (AML) and myelodaysplastic syndrome (MDS) (target undisclosed)

Senl_GDSTCLDxx (undisclosed): Universal CAR-GDT for certain type of solid tumors (target undisclosed)

Senl_BCMA03: Anti-BCMA CAR-T for R/R Multiple Myeloma (MM)

Senl_comboCARs(Senl_TAAx22P): Combo/customized anti-tumor associated antigen (TAA) and anti-CD22/PD-L1 CAR-T for sarcomas, ovarian cancer and other solid tumors

Senl_armTILs: Armored tumor infiltrating lymphocytes for solid tumors

Competitive Advantages

Total solutions in CellTech industry sector with seamless integration of innovative research, process development, standardization, validation, quality assessment/ quality control, bio-manufacturing, and clinical development, therefore, greatly accelerate translation of technology to clinical application as well as lower overall manufacturing costs.

Diverse and broad repertoire of pipeline candidates covering solid and hematologic malignancies; including both autologous and universal ("off-the-shelf") cell therapy candidates.

Advance cell/gene engineering and proprietary cell expansion expertise to enable design and development of celltherapy candidates with superior therapeutic efficacy and safety profile.

Our differentiating competence is mainly attributed by our capability to achieve seamless integration of our innovative research, broad repertoire of pipeline candidates, state-of-the-art bio-manufacturing/bio-processing infrastructure, as well as rapid implementation of clinical programs.

快乐飞艇综合走势图 快乐飞艇做任务靠谱吗 熊猫乐园快乐飞艇 华创投资快乐飞艇靠谱吗 快乐飞艇app首页 快乐飞艇计划 快乐飞艇app下载 快乐飞艇官网 快乐飞艇技巧 快乐飞艇开奖